Participant demographics. * P-values were determined using Fisher-Freeman-Halton test when contingency tables are larger than 2 × 2. by Elie Mulhem (22537863)

PRCC values (with <i>p</i>-values in parentheses) for the median final population size and difference in mean MSI at the final time, without weevil predation and with weevil predat... by Alexandra M. Campbell (3284094)

Subjects:

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…Each sample is a simulation of the entire assembly process for a scenario. Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …”

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Proportion of the increase (green) or decrease (red) in forest cover in areas with different fire recurrences in Africa, according to the Mann-Kendall test and statistically significance values. by Oswaldo Maillard (20660661)

Subjects:

Theta (Θ) vs Phi (Φ) joint contact force (JCF) vector path of increased and decreased strength conditions in comparison to default condition (100%). by Jay R. Patel (11600758)

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

Subjects:

Scheme of g-λ model with larger values λ. by Zhanfeng Fan (20390992)

“…And if the value of λ assumes larger values, the distortion in the shape of the transmitted wave is associated with the plastic deformation in the uncoupled rock mass. …”

Biases in larger populations. by Sander W. Keemink (21253563)

“…<p>(<b>A</b>) Maximum absolute bias vs the number of neurons in the population for the Bayesian decoder. Bias decreases with increasing neurons in the population. …”

Relationship between monthly NDVI and climatic variables values (Tmax, maximum air temperature; P, precipitation; VPD, vapor pressure deficit), in areas with decreasing trends (<i>p</i> < 0.05). by Oswaldo Maillard (20660661)

Subjects: